Incorporated in 2017, Faberco Life Sciences Inc. emerged with a steadfast commitment to making a significant impact in the healthcare landscape of the Philippines. Our goal is to provide safe, high-quality, cost-effective medicines and vaccines, specifically targeting infectious diseases. Over the years, our dedication to public health advocacy, coupled with the excellence and collaboration of our team, has established a strong presence in both the public and private sectors.
Our portfolio comprises vaccines that protect against vaccine preventable diseases, antiretroviral drugs for the treatment of HIV, and the country’s first HIV self-test licensed by the Philippine Food and Drug Administration.
The information provided in this section is for reference purposes only and not intended as a substitute for professional medical advice. Always consult your physician before using any prescription drugs and seek medical advice for any medical condition.
A sterile suspension of three types of poliovirus. It is a highly purified, inactivated poliovirus vaccine indicated for active immunization of infants (from 6 weeks of age), children and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2 and 3.
For active immunization against invasive diseases, pneumonia and acute otitis media caused by Streptococcus pneumoniae serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F & 23F in infants and toddlers from 6 weeks up to two years of age.
A Liquid Bovine Human Reassortant Rotavirus Pentavalent Vaccine. The vaccine constitutes five viruses of serotype G1, G2, G3, G4, and G9.
Indicated for active immunization of healthy infants from the age of 6 weeks for the prevention of gastroenteritis due to rotavirus infection when administered as a 3-dose series.
An integrated blood-based HIV self-test device that offers lay users, simple at-home HIV screening test with result in just 15 minutes.
50 mg/ 200 mg/ 25 mg film coated tablet
Indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1)
A fixed dose combination of tenofovir disoproxil fumarate, lamivudine and efavirenz. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and adolescents (from 12 years of age and weighing ≥ 40 kg) with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.
300mg Lamivudine, 300mg Tenofovir Disoproxil Fumarate, 50mg Dolutegravir Film Coated Tablet
Indicated for the treatment of human immunodeficiency virus (HIV) infection in adults and adolescents weighing at least 30 kg.
Dolutegravir (as sodium) is indicated, in combination with other antiretroviral medicines, for the treatment of human immunodeficiency virus (HIV) infection in patients weighing at least 20 kg.
Sugar-coated hormonal contraceptive tablet containing Levonorgestrel 150 mcg and Ethinylestradiol 30 mcg with Inert Tablets
Our streamlined commercialization process ensures that essential healthcare products reach professionals and institutions promptly, facilitating timely treatment and prevention for patients in need.
Globally, rotavirus remains the leading cause of diarrheal deaths in children under five years old. In the Philippines, 6,500 cases
We are pleased to announce the successful completion of the Good Manufacturing Practice (GMP) inspection conducted by the Philippine Food
Faberco is proud to announce its recent partnership with Sinovac, a global leader in biopharmaceuticals. We seek partnerships with companies
Globally, rotavirus remains the leading cause of diarrheal deaths in children under five years old. In the Philippines, 6,500 cases
We are pleased to announce the successful completion of the Good Manufacturing Practice (GMP) inspection conducted by the Philippine Food
Faberco is proud to announce its recent partnership with Sinovac, a global leader in biopharmaceuticals. We seek partnerships with companies
By submitting this form, you agree to have carefully read and understood Privacy Notice as described in our privacy policy in compliance with R.A. 10173 or the Data Privacy Act of 2012.
